Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Phase I/II Study of Myeloablative Anti-CD20+ Radioimmunotherapy with I-131-Rituximab in High-Risk CD20-Positive Non Hodgkin Lymphoma

Kathleen Schwarz, MD, Wagner Julia, MD, Susanne Schreiber, MD, Burkhard Schmidt, MD, Alexander Hoellein, MD, Mareike Verbeek, MD, Markus Schwaiger, MD, Christian Peschel, MD, Klemens Scheidhauer, MD, Christoph von Schilling, MD, Ulrich Keller, MD

Blood (2012) 120 (21): 3700.

https://doi.org/10.1182/blood.V120.21.3700.3700

Published: 2012

Journal Articles

Peripheral Blood Stem-Cell Mobilisation and Autologous Stem Cell Transplantation In HIV-Related Malignancies.

Marcus Hentrich, MD, Xaver Schiel, Fuat Oduncu, Arthur Gerl, Clemens Scheidegger, Christoph von Schilling, Ludwig Lutz, Meinolf Karthaus

Blood (2010) 116 (21): 4592.

https://doi.org/10.1182/blood.V116.21.4592.4592

Published: 2010

Journal Articles

The Economic Burden of Chemotherapy-Induced Toxicity in Lymphoma and NSCLC Routine Hospital Care

Angela Ihbe-Heffinger, MS, PhD, Bernadette JL Paessens, MS, PhD, Karin Berger, MS, Birgit Ehlken, MS, Margarita Shlaen, MS, Rudolf Bernard, MS, Christian Peschel, MD, Christoph von Schilling, MD

Blood (2008) 112 (11): 4701.

https://doi.org/10.1182/blood.V112.11.4701.4701

Published: 2008

Journal Articles

Resource Use and Costs Associated with Routine Management of Febrile Neutropenia in German Hospitals.

Angela Ihbe-Heffinger, MS, PhD, Bernadette Paessens, MS, Volker R. Jacobs, MD, PhD, MBA, Birgit Ehlken, MS, Margarita Shlaen, MPH, Karin Berger, MPH, Rudolf Bernard, MS, Christian Peschel, MD, PhD, Anita Goertz, MS, MPH, Christoph von Schilling, MD, PHD

Blood (2007) 110 (11): 3338.

https://doi.org/10.1182/blood.V110.11.3338.3338

Published: 2007

Journal Articles

Y-90 Ibritumomab Tiuxetan as Consolidation Following Three Cycles of Fludarabine-Cyclophosphamide-Rituximab Chemoimmunotherapy in Patients with Relapsed Follicular, Indolent or Mantle-Cell Lymphoma: A Prospective “Dose”-Finding Study.

Christoph von Schilling, MD, Kathleen Schwarz, MD, Georg Hess, MD., Ph.D., Andreas Viardot, MD, Michael Sandherr, MD, Stefan Krause, MD., Ph.D., Jan P. Simon, MD, Ph.D., Nadine Roethling, Christian Peschel, MD, Ph.D., Markus Schwaiger, MD, Ph.D., Klemens Scheidhauer, MD, Ph.D.

Blood (2007) 110 (11): 3426.

https://doi.org/10.1182/blood.V110.11.3426.3426

Published: 2007

Journal Articles

Efficacy and Safety of a Single-Course of Yttrium-90 Ibritumomab Tiuxetan for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma after/not Appropriate for Autologous Stem Cell Transplantation - Final Analysis of a Phase II Trial of the European MCL Network.

Oliver Weigert, MD, Christoph von Schilling, MD PhD, Mathias J. Rummel, MD PhD, Antonio Pezzutto, MD PhD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD PhD, Martin H. Dreyling, MD PhD

Blood (2007) 110 (11): 4501.

https://doi.org/10.1182/blood.V110.11.4501.4501

Published: 2007

Journal Articles

High Dose Cytarabine Salvage Regimen Combined with Bortezomib Is Feasible and Highly Effective in Relapsed Mantle Cell Lymphoma.

Oliver Weigert, MD, Eckhart Weidmann, MD, Rudolf Mueck, MD, Martin Bentz, MD, Christoph von Schilling, MD, Robert Rohrberg, MD, Kathleen Jentsch-Ullrich, MD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD, Martin H. Dreyling, MD

Blood (2006) 108 (11): 2449.

https://doi.org/10.1182/blood.V108.11.2449.2449

Published: 2006

Journal Articles

Bortezomib in Combination with High-Dose Dexamethasone and Continuous Low-Dose Oral Cyclophosphamide for Relapsed Multiple Myeloma.

Martin Kropff, MD, Guido Bisping, MD, Peter Liebisch, MD, Orhan Sezer, MD, Hermann Einsele, MD, Christian Straka, MD, Nicolaus Kroeger, MD, Bernd Metzner, MD, Monika Engelhardt, MD, Nicola Lang, MD, Marcus Hentrich, MD, Hans Wolf, MD, Christoph von Schilling, MD, Hans Salwender, MD, Wolfgang E. Berdel, MD, Joachim Kienast, MD

Blood (2005) 106 (11): 2549.

https://doi.org/10.1182/blood.V106.11.2549.2549

Published: 2005

Journal Articles

Efficacy and Safety of a Single-Course of Yttrium-90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) After/Not Appropriate for Autologous Stem Cell Transplantation (ASCT) - A Phase II Trial of the European MCL Network.

Oliver Weigert, MD, Christoph von Schilling, MD, PhD, Mathias J. Rummel, MD, PhD, Antonio Pezzutto, MD, PhD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD, PhD, Martin Dreyling, MD, PhD

Blood (2005) 106 (11): 4786.

https://doi.org/10.1182/blood.V106.11.4786.4786

Published: 2005

Journal Articles

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

Dieter Huhn, Christoph von Schilling, Martin Wilhelm, Anthony D. Ho, Michael Hallek, Rolf Kuse, Wolfgang Knauf, Ute Riedel, Axel Hinke, Stefanie Srock, Stefan Serke, Christian Peschel, Bertold Emmerich

Blood (2001) 98 (5): 1326–1331.

https://doi.org/10.1182/blood.V98.5.1326

Published: 2001

NARROW

Phase I/II Study of Myeloablative Anti-CD20+ Radioimmunotherapy with I-131-Rituximab in High-Risk CD20-Positive Non Hodgkin Lymphoma

Peripheral Blood Stem-Cell Mobilisation and Autologous Stem Cell Transplantation In HIV-Related Malignancies.

The Economic Burden of Chemotherapy-Induced Toxicity in Lymphoma and NSCLC Routine Hospital Care

Resource Use and Costs Associated with Routine Management of Febrile Neutropenia in German Hospitals.

Y-90 Ibritumomab Tiuxetan as Consolidation Following Three Cycles of Fludarabine-Cyclophosphamide-Rituximab Chemoimmunotherapy in Patients with Relapsed Follicular, Indolent or Mantle-Cell Lymphoma: A Prospective “Dose”-Finding Study.

Efficacy and Safety of a Single-Course of Yttrium-90 Ibritumomab Tiuxetan for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma after/not Appropriate for Autologous Stem Cell Transplantation - Final Analysis of a Phase II Trial of the European MCL Network.

High Dose Cytarabine Salvage Regimen Combined with Bortezomib Is Feasible and Highly Effective in Relapsed Mantle Cell Lymphoma.

Bortezomib in Combination with High-Dose Dexamethasone and Continuous Low-Dose Oral Cyclophosphamide for Relapsed Multiple Myeloma.

Efficacy and Safety of a Single-Course of Yttrium-90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) After/Not Appropriate for Autologous Stem Cell Transplantation (ASCT) - A Phase II Trial of the European MCL Network.

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only